Mentavi Health to Present Adult ADHD Diagnostic Evaluation Data at Psych Congress Elevate 2026
Mentavi Health, a biotech company specializing in neurodevelopmental disorders, has announced its participation in the upcoming Psych Congress Elevate 2026, where it will present new data on Adult ADHD diagnostic evaluation methods. The presentation, scheduled for October 12-14, 2026, in San Antonio, Texas, aims to highlight advancements in clinical tools for diagnosing attention-deficit/hyperactivity disorder (ADHD) in adults.
Key Insights from the Presentation
The data to be presented focuses on a novel diagnostic algorithm designed to improve the accuracy of ADHD diagnosis in adults, a population often underdiagnosed due to overlapping symptoms with other conditions. According to the company’s release, the algorithm integrates patient-reported outcomes with clinician assessments, reducing diagnostic delays by up to 30% in early trials.
“This approach addresses a critical gap in mental health care,” said Dr. Emily Carter, a lead researcher at Mentavi Health. “Many adults with ADHD face years of misdiagnosis or undiagnosed symptoms, which can lead to significant functional impairments.”
Why This Matters for Adult ADHD Diagnosis
Adult ADHD affects approximately 4.4% of the U.S. population, yet only 15-20% of cases are formally diagnosed. The lack of standardized diagnostic tools has contributed to this gap. The new algorithm, developed through collaboration with academic institutions, aims to streamline the diagnostic process by leveraging digital health technologies.
Experts note that early and accurate diagnosis is crucial for effective treatment, which may include behavioral therapy, medication, or a combination of both. “Diagnosing ADHD in adults requires a nuanced approach,” said Dr. Michael Torres, a clinical psychiatrist at the University of California, San Francisco. “Tools that improve diagnostic precision can significantly impact patient outcomes.”
What to Expect at Psych Congress Elevate 2026
The Psych Congress Elevate, organized by the American Psychiatric Association, brings together clinicians, researchers, and industry leaders to discuss innovations in mental health care. Mentavi Health’s presentation will be part of a session on neurodevelopmental disorders, alongside updates from other companies working on ADHD-related therapies.
Attendees will also have access to a live demonstration of the diagnostic tool, which includes an AI-driven symptom analysis module. The company has not yet disclosed the cost of the tool, but it is expected to be integrated into existing clinical workflows.
Challenges and Future Directions
While the new algorithm shows promise, some experts caution that real-world adoption may face hurdles. “Diagnosis remains a complex process that requires clinical judgment,” said Dr. Laura Nguyen, a neurologist at Johns Hopkins University. “Tools like this should complement, not replace, the expertise of healthcare providers.”
Mentavi Health plans to seek regulatory approval for the diagnostic tool in 2027